NCT03453801View on ClinicalTrials.gov

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 14, 2019

Study Completion Date

January 14, 2019

Conditions
InfluenzaHealthy
Interventions
BIOLOGICAL

Fluzone®

Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.

BIOLOGICAL

FluMist®

FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection | Biotech Hunter | Biotech Hunter